CG0070 is investigated in clinical trials for treating bladder cancer. CG0070 is a solid. CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus... CG0070, an oncolytic virus therapy with specificity for multiple cancers, has been evaluated in numerous preclinical studies.
- Mechanism
- Curator reviewed
CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF. CG7870 is a genetically modified adenovirus designed to replicate in prostate cancer cells by utilizing prostate selective transcription elements to control the key early viral genes E1a and E1b. CG0070 is a replication competent adenovirus that has been shown pre-clinically to preferentially replicate in RB pathway defective cells and express the cytokine gene GM-CSF.
- Primary indication
- Investigated for use/treatment in bladder cancer.Curator reviewed
- Also known as
- Cretostimogene Grenadenore
- Code names
- CG-0070
Resolves to
What you can answer from here — as of September 03, 2026
Which drugs share a target with Cretostimogene grenadenorepvec, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account